For the year ending 2025-12-31, GUTS had $14,076K increase in cash & cash equivalents over the period. -$90,885K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -140,954 |
| Depreciation | 1,129 |
| Non-cash interest expense | 296 |
| Non-cash operating lease expense | 1,587 |
| Stock-based compensation expense | 6,684 |
| Change in fair value of warrant liabilities | 40,901 |
| Change in fair value of notes payable, non-cash | 424 |
| Inventory | -73 |
| Prepaid expenses and other current assets | -2,248 |
| Accounts payable | -1,666 |
| Accrued expenses and other current liabilities | 414 |
| Operating lease liabilities | -1,278 |
| Other long-term assets and liabilities | 186 |
| Net cash used in operating activities | -90,328 |
| Purchases of property and equipment | 557 |
| Net cash used in investing activities | -557 |
| Issuance of common stock in connection with at-the-market offering, net of underwriting commissions and offering costs | 6,778 |
| Issuance of common stock and warrants in august 2025 public offering, net of underwriting commissions and offering costs | 22,587 |
| Issuance of common stock in september 2025 public offering, net of underwriting commissions and offering costs | 56,016 |
| Proceeds from issuance of common stock under share purchase agreement | 20 |
| Exercises of common stock warrants | 19,737 |
| Exercises of common stock options | 280 |
| Principal payments on finance lease obligations | 457 |
| Net cash provided by financing activities | 104,961 |
| Net increase in cash, cash equivalents and restricted cash | 14,076 |
| Cash, cash equivalents and restricted cash at beginning of period | 71,719 |
| Cash, cash equivalents and restricted cash at end of period | 85,795 |
FRACTYL HEALTH, INC. (GUTS)
FRACTYL HEALTH, INC. (GUTS)